SCHEMBL6584126

SCHEMBL6584126

NC(=O)Oc1cccc2[nH]c(-c3ccc(-n4ccc(CN5CCCCC5)c4)cc3)nc12

nearest known ligand 0.77

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 3/20 0.77
KDR P35968 2/20 0.77
PARP1 P09874 12/20 0.58
DHODH Q02127 3/20 0.50
GRIN2B Q13224 4/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 2/20 0.46
GRIN1 Q05586 1/20 0.41
AURKA O14965 2/20 0.41
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6581347 0.92 AURKB (0.65) AURKBKDRPARP1DHODHGRIN2B
SCHEMBL6581349 0.92 AURKB (0.64) AURKBKDRPARP1DHODHGRIN2B
SCHEMBL6381152 0.88 PARP1 (0.73) AURKBKDRPARP1DHODHGRIN2B
SCHEMBL6383679 0.87 PARP1 (0.72) AURKBKDRPARP1DHODHGRIN2B
SCHEMBL3577924 0.87 AURKB (1.00) AURKBKDRPARP1DHODHAURKA
SCHEMBL6580981 0.86 KDR (0.56) AURKBKDRPARP1DHODHHDAC6
SCHEMBL6381588 0.83 PARP1 (0.74) AURKBKDRPARP1DHODHGRIN2B
SCHEMBL6582934 0.82 AURKB (0.51) AURKBKDRPARP1AURKA
SCHEMBL6384291 0.82 PARP1 (0.73) AURKBKDRPARP1DHODHGRIN2B
SCHEMBL6580774 0.81 PARP1 (0.56) AURKBKDRPARP1DHODHGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1391457-B1 Substituted 2-Phenylbenzimidazoles and their use as PARP inhibitors ABBVIE DEUTSCHLAND (DE) 2013-12-25 EP disclosed
EP-1127052-B1 SUBSTITUTED 2-PHENYLBENZIMIDAZOLES, THE PRODUCTION THEREOF AND THEIR USE ABBOTT GMBH & CO KG (DE) 2004-12-08 EP disclosed
EP-1391457-A1 Substituted 2-Phenylbenzimidazoles and their use as PARP inhibitors Abbott GmbH & Co. KG (DE) 2004-02-25 EP disclosed